The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2434-2444

  Schuchmann, M ^a   Meyer, R G ^a   Distler, E ^a   Von Stebut, E ^a   Kuball, J ^b   Schnurer E ^a   Wolfel T ^a   Theobald, M ^b   Konur, A ^a   Gregor, S ^a   Schreiner, O ^a   Huber, C ^a   Galle, P R ^a   Otto, G ^a   Herr, W ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alloreactive T cells; Chimerism; Graft versus host disease (GVHD); Liver transplantation; Tolerance

Indexed keywords

ALEMTUZUMAB; APOPTOSIS REGULATORY PROTEIN; BASILIXIMAB; CYCLOSPORIN; PREDNISOLONE; PROGRAMMED CELL DEATH 1; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW CELL; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHIMERA; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER TRANSPLANTATION; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED;

EID: 53749095064     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02401.x     Document Type: Article

References (50)

1. Burdick JF, Vogelsang GB, Smith WJ et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 1988 318 : 689 691.
2. Sliman GA, Beschorner WE, Baughman KL, Hutchins GM, Borkon MA, Baumgartner WA. Graft-versus-host-like disease in a heart allograft recipient. A possible autoimmune phenomenon. Transplantation 1988 45 : 253 256.
3. Weinstein A, Dexter D, KuKuruga DL, Philosophe B, Hess J, Klassen D. Acute graft-versus-host disease in pancreas transplantation: A comparison of two case presentations and a review of the literature. Transplantation 2006 82 : 127 131.
4. Assi MA, Pulido JS, Peters SG, McCannel CA, Razonable RR. Graft-vs.-host disease in lung and other solid organ transplant recipients. Clin Transplant 2007 21 : 1 6.
5. Smith DM, Agura E, Netto G et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003 75 : 118 126.
6. Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: The enemy within. Am J Transplant 2004 4 : 466 474.
7. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001 98 : 3192 3204.
8. Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: Patterns of lymphocyte chimerism. Am J Transplant 2005 5 : 2968 2973.
9. Norris S, Collins C, Doherty DG et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998 28 : 84 90.
10. Collins RH Jr., Anastasi J, Terstappen LW et al. Brief report: Donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med 1993 328 : 762 765.
11. Meves A, el-Azhary RA, Talwalkar JA et al. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol 2006 55 : 642 646.
12. Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001 1 : 233 239.
13. Starzl TE. Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A 2004 101 (Suppl 2 S14607 S14614.
14. Kurtz J, Wekerle T, Sykes M. Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol 2004 25 : 518 523.
15. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992 11 : 3887 3895.
16. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006 27 : 195 201.
17. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999 11 : 141 151.
18. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006 203 : 883 895.
19. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995 15 : 825 828.
20. Kuball J, Theobald M, Ferreira EA et al. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation 2004 78 : 1774 1779.
21. Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tuting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 2007 157 : 752 757.
22. Berger AE, Davis JE, Cresswell P. Monoclonal antibody to HLA-A3. Hybridoma 1982 1 : 87 90.
23. Meyer RG, Britten CM, Wehler D et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007 109 : 374 382.
24. Wehler TC, Nonn M, Brandt B et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007 109 : 365 373.
25. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002 259 : 95 110.
26. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: A novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003 170 : 4069 4076.
27. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978 14 : 9 20.
28. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980 125 : 293 299.
29. Perri R, Assi M, Talwalkar J et al. Graft vs. host disease after liver transplantation: A new approach is needed. Liver Transpl 2007 13 : 1092 1099.
30. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992 339 : 1579 1582.
31. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008 358 : 353 361.
32. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003 3 : 199 210.
33. Demirkiran A, Bosma BM, Kok A et al. Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007 178 : 6066 6072.
34. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007 7 : 585 598.
35. Trautmann L, Janbazian L, Chomont N et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006 12 : 1198 1202.
36. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006 443 : 350 354.
37. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439 : 682 687.
38. Petrovas C, Casazza JP, Brenchley JM et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006 203 : 2281 2292.
39. Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007 178 : 2714 2720.
40. Blank C, Kuball J, Voelkl S et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006 119 : 317 327.
41. Ozkaynak E, Wang L, Goodearl A et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002 169 : 6546 6553.
42. Blazar BR, Carreno BM, Panoskaltsis-Mortari A et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003 171 : 1272 1277.
43. Sandner SE, Clarkson MR, Salama AD et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005 174 : 3408 3415.
44. Schilbach K, Schick J, Wehrmann M et al. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating T cells during murine GVHD across minor histocompatibility antigen barriers. Transplantation 2007 84 : 214 222.
45. Tanaka K, Albin MJ, Yuan X et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 179 : 5204 5210.
46. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 2007 19 : 813 824.
47. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000 192 : 1027 1034.
48. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002 169 : 3581 3588.
49. Youngnak-Piboonratanakit P, Tsushima F, Otsuki N et al. The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunol Lett 2004 94 : 215 222.
50. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007 7 : 340 352.